flotufolastat f 18

Flotufolastat f 18 is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging to detect prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. It is indicated for use in patients with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels. The drug works by binding to PSMA, which is overexpressed on the surface of prostate cancer cells, and is then internalized by these cells. The fluorine-18 component emits positrons detectable by PET imaging, allowing precise localization of PSMA-positive lesions. Flotufolastat f 18 was developed using proprietary radiohybrid (rh) technology and represents the first FDA-approved PSMA-targeted imaging agent of its kind[2][6][7].

Brand names

Posluma

Other names

flotufolastat F-18rhPSMA-7.3rhPSMA7.3rhPSMA 7.3